These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 30776984)

  • 1. Improving Outcomes in Patients With Diabetes Mellitus.
    Aguilar D
    J Am Heart Assoc; 2019 Feb; 8(4):e011971. PubMed ID: 30776984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response by Sattar et al to Letters Regarding Article, "Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks".
    Sattar N; Rawshani A; Franzen S
    Circulation; 2019 Oct; 140(16):e724-e725. PubMed ID: 31609663
    [No Abstract]   [Full Text] [Related]  

  • 3. Letter by Wang et al Regarding Article, "Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks".
    Wang D; Chen T; Yang X
    Circulation; 2019 Oct; 140(16):e720-e721. PubMed ID: 31609657
    [No Abstract]   [Full Text] [Related]  

  • 4. The Ongoing Saga of Optimal Blood Pressure Level in Patients With Diabetes Mellitus and Coronary Artery Disease.
    Deedwania P
    J Am Heart Assoc; 2018 Oct; 7(20):e010752. PubMed ID: 30371267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capsule Commentary for Raghavan et al., Association of Glycemic Control Trajectory with Short-term Mortality in Diabetes Patients with High Cardiovascular Risk: a Joint Latent Class Modeling Study.
    Blaszak SC; Nye DG; Walton HH
    J Gen Intern Med; 2020 Aug; 35(8):2518. PubMed ID: 32424784
    [No Abstract]   [Full Text] [Related]  

  • 6. Letter by Wang and Xu Regarding Article, "Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks".
    Wang J; Xu Y
    Circulation; 2019 Oct; 140(16):e722-e723. PubMed ID: 31609662
    [No Abstract]   [Full Text] [Related]  

  • 7. Excess Cardiovascular Risk in Type 1 Diabetes Mellitus.
    Petrie JR; Sattar N
    Circulation; 2019 Feb; 139(6):744-747. PubMed ID: 30715940
    [No Abstract]   [Full Text] [Related]  

  • 8. With regard to the papers by Kumar et al. and de Leeuw and de Boer addressing the cardiovascular safety and efficacy of anti-diabetic drugs.
    Turner JR; Caveney E; Gillespie BS; Karnad DR; Kothari S; Metz A; Keller LH
    Eur Heart J Cardiovasc Pharmacother; 2017 Apr; 3(2):75-76. PubMed ID: 28122792
    [No Abstract]   [Full Text] [Related]  

  • 9. Letter by Tampakis et al Regarding Article, "Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease".
    Tampakis A; Tampaki EC; Gürke L
    Circulation; 2018 Aug; 138(8):848-849. PubMed ID: 30359125
    [No Abstract]   [Full Text] [Related]  

  • 10. Response by Wanner et al to Letters Regarding Article, "Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease".
    Wanner C; von Eynatten M; Zinman B
    Circulation; 2018 Aug; 138(8):850-851. PubMed ID: 30359123
    [No Abstract]   [Full Text] [Related]  

  • 11. Comment on Cheng et al. Trends and Disparities in Cardiovascular Mortality Among U.S. Adults With and Without Self-Reported Diabetes, 1988-2015. Diabetes Care 2018;41:2306-2315.
    Manicardi V; Vicentini M; Ballotari P; Venturelli F; Giorgi Rossi P
    Diabetes Care; 2019 Apr; 42(4):e62. PubMed ID: 30894386
    [No Abstract]   [Full Text] [Related]  

  • 12. Response to Comment on Cheng et al. Trends and Disparities in Cardiovascular Mortality Among U.S. Adults With and Without Self-Reported Diabetes, 1988-2015. Diabetes Care 2018;41:2306-2315.
    Cheng YJ; Imperatore G; Albright AL; Gregg EW
    Diabetes Care; 2019 Apr; 42(4):e63. PubMed ID: 30894387
    [No Abstract]   [Full Text] [Related]  

  • 13. Where diabetes care meets cardiovascular research: our cardiovascular perspective at a Centre devoted to diabetes research and care.
    Fadini GP; Vigili de Kreutzenberg S; Avogaro A
    Eur Heart J; 2021 Jul; 42(25):2417-2419. PubMed ID: 33755089
    [No Abstract]   [Full Text] [Related]  

  • 14. Precision medicine for diabetes management and primary cardiovascular prevention.
    Leggio M; Tiberti C; Armeni M; Limongelli G; Mazza A
    J Intern Med; 2019 Jul; 286(1):112-114. PubMed ID: 30957916
    [No Abstract]   [Full Text] [Related]  

  • 15. Diabetes and cardiovascular mortality: the impact of sex.
    Norhammar A
    Lancet Diabetes Endocrinol; 2018 Jul; 6(7):517-519. PubMed ID: 29752193
    [No Abstract]   [Full Text] [Related]  

  • 16. Response by Zinman et al to Letter Regarding Article, "Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk".
    Zinman B; Inzucchi SE; Diener HC
    Stroke; 2017 Sep; 48(9):e256-e257. PubMed ID: 28701577
    [No Abstract]   [Full Text] [Related]  

  • 17. J. Vouillarmet et al. in response to V. Aboyans et al. concerning the article by M. Helfre et al.: Usefulness of a systematic screening of carotid atherosclerosis in asymptomatic people with type 2 diabetes for cardiovascular risk reclassification. Ann Endocrinol (Paris). 2017;78:14-19.
    Vouillarmet J; Helfre M; Grange C
    Ann Endocrinol (Paris); 2018 Apr; 79(2):89-90. PubMed ID: 29530272
    [No Abstract]   [Full Text] [Related]  

  • 18. Letter by Tampaki et al Regarding Article, "Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk".
    Tampaki EC; Tampakis A; Gürke L
    Stroke; 2017 Sep; 48(9):e255. PubMed ID: 28701575
    [No Abstract]   [Full Text] [Related]  

  • 19. Semaglutide is non-inferior to placebo for cardiovascular outcomes in patients with type 2 diabetes.
    Campbell-Scherer D
    Evid Based Med; 2017 Apr; 22(2):57-58. PubMed ID: 28270434
    [No Abstract]   [Full Text] [Related]  

  • 20. Adding exercise to usual care in patients with hypertension, type 2 diabetes mellitus and/or cardiovascular disease: a protocol for a systematic review with meta-analysis and trial sequential analysis.
    Rijal A; Nielsen EE; Hemmingsen B; Neupane D; Gæde PH; Olsen MH; Jakobsen JC
    Syst Rev; 2019 Dec; 8(1):330. PubMed ID: 31847918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.